myLaurel®, a healthtech company redefining what’s possible in hospital-at-home delivery, has raised $12 million in fresh funding. The round was led by a powerhouse group of investors including Deerfield Management, Google Ventures (GV), Emerson Collective, Ochsner Health, and Pinta Partners.

Founded by Juan Vallarino, myLaurel delivers high-acuity care - including remote diagnostics, physician-guided treatment, and 24/7 care coordination - in the patient’s home, especially for those managing multiple chronic conditions. The platform blends telemedicine, home health services, and extended post-discharge care into one seamless experience.

---

What Is myLaurel?

myLaurel is a tech-enabled clinical platform built for delivering hospital-level care at home for high-complexity patients - those who would otherwise require frequent readmissions, long hospital stays, or intensive outpatient monitoring.

Key features include:

• Rapid-response in-home provider visits and diagnostics
  
• Integrated telehealth and remote vitals monitoring
  
• Customized care plans managed by clinical teams
  
• Coordination with hospitals and primary care networks to prevent readmissions
  

By intervening early and continuing care beyond discharge, myLaurel lowers the risk of hospitalization and enhances outcomes for patients who are often medically fragile or underserved by conventional care.

---

The Rising Demand for Home-Based Acute Care

The healthcare industry is in the middle of a massive care-shift moment. According to McKinsey & Company, up to $265 billion worth of care services (representing 25% of all Medicare spending) could transition from traditional facilities to the home by 2025.

At the same time, CMS has expanded reimbursement policies under its Acute Hospital Care at Home waiver, which now includes over 300 hospitals across 37 states. Data from these pilots shows that hospital-at-home care:

• Reduces length of stay by up to 32%
  
• Cuts 30-day readmission rates by 20–30%
  
• Achieves equal or better outcomes compared to in-hospital treatment
  

Meanwhile, Precedence Research estimates the global home healthcare market will grow to $660 billion by 2030, with complex chronic care and value-based models leading the charge.

myLaurel is positioned right at the intersection of these trends: delivering measurable cost savings while improving outcomes for the most underserved and clinically challenging patients.

---

Why This Raise Is a Signal for the Industry

What makes myLaurel’s $12 million round stand out isn’t just the size or investor list - it’s the message behind it. This round validates a broader truth: acute care no longer has to be delivered within hospital walls.

By focusing on complex cases rather than convenience care, myLaurel has moved past the typical telehealth playbook. It’s not just offering virtual checkups. It’s building a fully integrated clinical operations stack that brings diagnostics, nurses, and physicians directly to the patient - then stays with them through recovery.

And here’s where the strategy gets sharper: most digital health startups chase the “easy-on” market - low-acuity care, teleconsults, general monitoring. It’s faster to scale, easier to implement, and less risky. But in healthcare, value isn’t created at the margins. It’s created at the edges - where the pain, complexity, and cost are highest.

myLaurel did the opposite of what many seed-stage companies would do. Instead of optimizing for fast onboarding or light infrastructure, they leaned into heavy ops, layered logistics, and serious clinical rigor. Why? Because they understood a principle too many founders ignore: the more difficult the problem, the more defensible the solution.

When you build for the hardest patients - the ones nobody else wants to touch - you don't just get market share. You get mission-critical relevance. You earn the attention of payers, hospital systems, and policymakers, not just patients.

So the insight is this: if you're a founder building in healthtech, don’t underestimate the compounding value of solving high-friction, high-cost use cases. They may take longer to crack, but once you do, you become indispensable - not optional.

---

The Market Outlook: High-Complexity Care, High-Growth Model

The global home healthcare market is projected to hit $660 billion by 2030, according to Precedence Research, growing at a CAGR of 8.5%. Within that, complex condition management is the fastest-growing segment, driven by:

• Increasing multi-morbidity in aging populations
  
• Government incentives to reduce hospital burden
  
• Hospital system investment in continuity of care solutions
  
• Digital health tools enabling earlier interventions at home
  

Meanwhile, venture investment in care-at-home platforms has grown 4x since 2020, with investors now prioritizing platforms that show cost control + clinical integration - precisely what myLaurel delivers.

---

What’s Next for myLaurel?

With this new funding, myLaurel plans to:

• Expand operations into new high-need metro areas
  
• Deepen payer and provider partnerships for integrated care
  
• Enhance care coordination software and predictive analytics
  
• Build out its clinical operations team and in-home rapid-response network
  
• Launch longitudinal care pathways for oncology, cardiac, and pulmonary patients
  

The company also aims to become a CMS-compliant platform partner in value-based care programs - cementing its role not just as a tech provider, but as a clinical operations partner.